These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 305966)

  • 41. Rejection of allogeneic and syngeneic but not MHC class I-deficient tumor grafts by MHC class I-deficient mice.
    Freland S; Chambers BJ; Andersson M; Van Kaer L; Ljunggren HG
    J Immunol; 1998 Jan; 160(2):572-9. PubMed ID: 9551890
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of inoculation with neuraminidase-treated tumor cells on macrophage cytotoxicity in vitro.
    Alley CD; Snodgrass MJ
    Cancer Res; 1978 Aug; 38(8):2332-8. PubMed ID: 667829
    [No Abstract]   [Full Text] [Related]  

  • 43. Facilitation and inhibition of b16 melanoma by BCG in vivo and by lymphoid cells from bcg-treated mice in vitro.
    Chee DO; Bodurtha AJ
    Int J Cancer; 1974 Jul; 14(1):137-43. PubMed ID: 4617706
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect of Bacillus Calmette-Guérin on the in vitro generation of cytotoxic T lymphocytes. II. Role of interleukin-1-like factors and of soluble suppressor factors.
    Mellow L; Sabbadini E
    Immunology; 1985 Oct; 56(2):235-43. PubMed ID: 2932383
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of BCG on cytostatic activity of peritoneal macrophages from normal and tumor-bearing rats.
    Chikama M; Saijo N; Irimajiri N; Niitani H
    Gan; 1979 Apr; 70(2):229-33. PubMed ID: 467886
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of preexisting tumor immunity on Bacillus Calmette-Guérin immunotherapy of guinea pigs with both regional and disseminated tumor.
    Jessup JM; Riggs CW; Hanna MG
    Cancer Res; 1977 Aug; 37(8 Pt 1):2565-73. PubMed ID: 872084
    [No Abstract]   [Full Text] [Related]  

  • 47. Lectin-dependent cell-mediated cytotoxicity: assessment of cytotoxic reactivity following challenge with syngeneic tumors.
    Laux DC; Parker BM; DiSciullo SO; Petrarca MA; McAllister CG
    J Natl Cancer Inst; 1984 Mar; 72(3):667-72. PubMed ID: 6583449
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BCG-induced murine effector cells. I. Cytolytic activity in peritoneal exudates: an early response to BCG.
    Tracey DE; Wolfe SA; Durdik JM; Henney CS
    J Immunol; 1977 Sep; 119(3):1145-51. PubMed ID: 330748
    [No Abstract]   [Full Text] [Related]  

  • 49. Selective induction and inhibition of direct and lectin-dependent cell-mediated cytotoxic reactivity.
    Parker BM; Laux DC
    Cell Immunol; 1981 Jul; 61(2):253-64. PubMed ID: 6788380
    [No Abstract]   [Full Text] [Related]  

  • 50. Dynamics of immunity in syngeneic lymphoma-bearing mice.
    Jurin M; Plavsić B
    Eur J Cancer (1965); 1978 Jun; 14(6):653-9. PubMed ID: 350589
    [No Abstract]   [Full Text] [Related]  

  • 51. Immune responses to mouse neuroblastoma C1300. II. Cell-mediated kinetics and specificity studies.
    Della Penta D; Cipuzak PM; Phillips ME
    Int Arch Allergy Appl Immunol; 1982; 69(4):322-9. PubMed ID: 7141715
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intratumor chemoimmunotherapy with mitomycin C and BCG in C3H/He mice transplanted with MH134.
    Kasuga M; Sakita M; Yamane T; Torii T; Tamai M; Kageyama N; Fujita Y; Majima S
    Gan; 1983 Feb; 74(1):148-54. PubMed ID: 6404684
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor cytokinetics in the presence of normal, alloimmune, or Bacillus Calmette-Guérin-activated host cells simultaneously assayed in vivo and in vitro.
    Normann SJ; Cornelius J
    Cancer Res; 1987 Apr; 47(8):2067-72. PubMed ID: 3828996
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Experimental cancer immunotherapy: comparison of tumor rejection if F344 rats given live Mycobacterium bovis (Strain BCG) and killed Corynebacterium parvum.
    Likhite VV
    J Natl Cancer Inst; 1976 May; 56(5):985-9. PubMed ID: 994209
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glucan: attempts to demonstrate therapeutic activity against five syngeneic tumors in guinea pigs and mice.
    Hunter JT; Meltzer MS; Ribi E; Fidler IJ; Hanna MG; Zbar B; Rapp HJ
    J Natl Cancer Inst; 1978 Feb; 60(2):419-24. PubMed ID: 202719
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of "lymphotoxin" in the local anti-tumour action associated with inflammation caused by delayed hypersensitivity responses or intralesional BCG. I. Variations in response of different syngeneic mouse tumours.
    Parr IB; Jackson LE; Alexander P
    Br J Cancer; 1983 Sep; 48(3):395-403. PubMed ID: 6604535
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Genetic variation of in vitro cytolytic activity and in vivo rejection potential of non-immunized semi-syngeneic mice against a mouse lymphoma line.
    Kiessling R; Petranyi G; Klein G; Wigzel H
    Int J Cancer; 1975 Jun; 15(6):933-40. PubMed ID: 1150347
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of BCG on B16 mouse melanoma: a comparison of routes of administration on tumour growth at different anatomical sites.
    Proctor JW; Auclair BG; Lewis MG
    Eur J Cancer (1965); 1976 Mar; 12(3):203-10. PubMed ID: 939237
    [No Abstract]   [Full Text] [Related]  

  • 60. Variations in the intensity of BCG-potentiated alloimmune anti-tumor responses: the differential stimulation of T-cell subpopulations.
    Davies M; Sabbadini E; Kendall L
    Immunobiology; 1981; 160(3-4):311-20. PubMed ID: 6799388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.